Does Dr. ALEXEY KNYAZHITSKIY have financial conflicts of interest?

Dr. ALEXEY KNYAZHITSKIY (M.D.) has received a total of $65,966 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $65,966 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ALEXEY KNYAZHITSKIY?

According to CMS Open Payments data, Dr. ALEXEY KNYAZHITSKIY received funding from MYLAN SPECIALTY L.P ($52,981), VIATRIS SPECIALTY ($12,002), and ASTRAZENECA PHARMACEUTICALS ($653).

Does Dr. ALEXEY KNYAZHITSKIY receive research grants or speaking fees?

Dr. ALEXEY KNYAZHITSKIY has received $65,966 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. ALEXEY KNYAZHITSKIY

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Pulmonary Disease

Practice Location: TAUNTON, MA 02780

NPI Number: 1942484092

LIFETIME INDUSTRY VALUE

$65,966

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. KNYAZHITSKIY is a verified Internal Medicine, Pulmonary Disease practitioner based in TAUNTON, MA.

Between 2021 and 2025, Dr. KNYAZHITSKIY had an overall industry promotional and research financial footprint of $65,966 as recorded in the federal CMS Open Payments database.

$65,966 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. KNYAZHITSKIY's primary funding source is MYLAN SPECIALTY L.P, which accounts for $52,981 (representing 80.3% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

MYLAN SPECIALTY L.P

Rank 1

$52,981

80.3%

VIATRIS SPECIALTY

Rank 2

$12,002

18.2%

ASTRAZENECA PHARMACEUTICALS

Rank 3

$653

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.